News Release

October 31, 2024

JCR Pharmaceuticals Co., Ltd.

Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)

Hyogo, Japan, October 31, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the purchase price in the "Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)" announced yesterday has been determined.

1. Repurchase price and total amount
   (1) Closing price today (October 31, 2024) 689 yen
   (2) Total amount of repurchase 2,583,750,000 yen (at maximum)

2. Method and details of repurchase (information announced yesterday)

(1) Method of repurchase
The Company will place a purchase order through brokerages on the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) for the 8:45 a.m. session on November 1, 2024 (no changes to other trading system or trading time shall be made). This purchase order will be limited to the aforementioned trading time.

(2) Class of share to be repurchased: Common stock of the Company

(3) Total number of shares to be repurchased: 3,750,000 shares (at maximum)
(2.98% of the total number of shares of common stock outstanding excluding treasury shares)

(4) Announcement of acquisition results: After the close of trading at 8:45 a.m. on November 1, 2024

(Note 1) The maximum number of shares to be repurchased will not be changed. Depending on market conditions etc., however, the Company may not make any purchase or may only make a partial purchase.

(Note 2) The repurchase will be conducted to the extent that sell orders match the number of shares to be repurchased.

(Reference)

The Company's own shares holding as of September 30, 2024

Total number of issued and outstanding shares (excluding treasury shares): 125,763,806 shares

Total number of own shares: 3,922,502 shares

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###